Skip to main content

Carlos A. Alemany, MD

Carlos A. Alemany, MD

Medical Director (Clinical Research), Medical Oncologist

Cancer

Carlos Alemany

Overview

Dr. Carlos Alemany, MD is a board-certified hematology and oncology physician in Orlando. Dr. Alemany earned his medical degree from Ponce School of Medicine in Ponce, Puerto Rico. He went on to complete a residency at the Cleveland Clinic Foundation in Cleveland, OH, staying there to pursue a fellowship as well. Dr. Alemany specializes in breast cancer and genitourinary malignancies. As an established member of the medical community, Dr. Alemany has authored and co-authored several articles in peer-reviewed medical journals on the topics of breast cancer, lung cancer, lymphoma, anemia, multiple myeloma, colon cancer and novel chemotherapy agents. An award-winning physician, Dr. Alemany has been recognized as one of the Best Doctors in America. He is fluent in both English and Spanish.

Articles

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study

CLINICAL BREAST CANCER

2019

A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple negative breast cancer

CANCER RESEARCH

2019

Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year Interval

JOURNAL OF ONCOLOGY PRACTICE

2015

Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor

CASE REPORTS IN ENDOCRINOLOGY

2015

Etirinotecan Pegol: Development of a Novel Conjugated Topoisomerase I Inhibitor

CURRENT ONCOLOGY REPORTS

2014

Education & Training

Education

Ponce School of Medicine, Ponce, Puerto Rico

Residency

The Cleveland Clinic Foundation, Cleveland, OH

Fellowship

The Cleveland Clinic Foundation, Cleveland, OH

Specialty

Medical Oncology

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT01872975

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Icon for trial | B-51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative A

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. ...

NCT02947685

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Icon for trial | AFT-38 A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positi

This research study is a Phase III clinical trial, which tests the safety, tolerability and effect of an investigational combination of drugs to learn whether the combination of drugs works for a specific cancer. Investigationa ...

NCT03773302

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Trial

Icon for trial | QBGJ398-301 A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Tria

This study is currently enrolling.

The PROOF Trial is a clinical research study to determine if the investigational drug, infigratinib, improves the treatment for cholangiocarcinoma compared with the standard of care, chemotherapy gemcitabine with cisplatin, for ...

NCT02997228

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Icon for trial | GI004 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Defi

This study is currently enrolling.

The purpose of this study is to learn if adding an experimental drug, atezolizumab (MPDL3280A), to a usual treatment or giving the experimental drug alone is better than the usual treatment alone.

NCT04071457

Phase III Study of Daratumumab/rHuPH20 (NSC - 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Icon for trial | S1803 Phase III Study of Daratumumab/rHuPH20 (NSC - 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMA

This study is currently enrolling.

This study is being done to answer the following questions: (1) Will adding the drug daratumumab/rHuPH20 to the usual maintenance treatment with lenalidomide after stem cell transplant help myeloma patients survive longer?; and ...

NCT02954874

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with greater than or equal to 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy.

Icon for trial | S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with greater than or equal to 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi,

This study is currently enrolling.

The purpose of this study is to compare the usual approach (no more treatment or additional chemotherapy and radiation therapy after surgery or radiation therapy alone after surgery), with any effects (good or bad) of receiving ...

NCT04241185

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with CHemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

Icon for trial | MK-3475-992 A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with CHemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer

This study is currently enrolling.

The purpose of this study is to (a) test the safety of the study drug, pembrolizumab, when given with chemoradiotherapy (CRT). CRT is a combination of chemotherapy and radiation therapy; (b) see if pembrolizumab and CRT control ...

NCT04002297

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Icon for trial | BGB-3111-306 A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantatio

This study is currently enrolling.

The purpose of this study is to compare the effects, good or bad, of an investigational anticancer drug called zanubrutinib (Z) (also known as BGB-3111) in combination with rituximab ®, versus commonly used treatment combinatio ...

NCT04305496

A Phase III Double-blind Randomised Study Assessing the EFficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291)

Icon for trial | D3615C00001 A Phase III Double-blind Randomised Study Assessing the EFficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Grow

This study is currently enrolling.

This study is being done to learn more about if the new medication called capivasertib given with one of the standards of care fulvestrant will work more effectively than fulvestrant alone in treating patients with advanced bre ...

NCT04505826

A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects with Advanced and/or Metastatic Hormone Receptor (HR)-positive, HER2-negative Breast Cancer

Icon for trial | OP-1250-001 A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects with Advanced and/or Metastatic Hormone Receptor (HR)-positive, HER2-negative Breast Cancer

This study is currently enrolling.

The purpose of this study is to (a) determine the highest dose that can safely be given without unacceptable (intolerable) side effects to subjects who have cancer; (b) determine the amount of OP-1250 in the blood of subjects w ...

NCT04266249

EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in Patients who Achieve a Pathologic Complete Response, Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic Response ASSessment to Optimize Therapy in HER2-positive Breast Cancer)

Icon for trial | EA1181 EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in Patients who Achieve a Pathologic Complete Response, Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic Response ASSessment to Optimize Therapy in HER2-pos

This study is currently enrolling.

This study is being done to answer the following question. Can participants with HER2-positive breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after 12 weeks of chemotherapy ...

NCT04478266

A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease

Icon for trial | EFC15935 A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for

This study is currently enrolling.

The purpose of the study is to evaluate whether SAR439859 (our experimental hormonal treatment) is a better option compared to Letrozole (a standard hormonal treatment), when given together with Palbociclib (Ibrance), in terms ...

NCT04586231

An Open-label, Randomized, Phase 2 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Icon for trial | MK-6482-011 An Open-label, Randomized, Phase 2 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L

This study is currently enrolling.

This trial is being done to test MK-6482 + lenvatinib in people with a type of kidney cancer called advanced clear cell Renal Cell Carcinoma (ccRCC). MK-6482 is still being researched and has not been approved to use alone or w ...

NCT04736706

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Icon for trial | MK-6482-012 An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-

This study is currently enrolling.

This trial is testing 3 combination therapies in people with a specific type of kidney cancer called advanced clear cell renal cell carcinoma (ccRCC). These 3 therapies are: (1) HIF triplet: pembrolizumab plus MK-6482 (belzutif ...

NCT04457596

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

Icon for trial | A011801 The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucati

This study is currently enrolling.

This study is being done to answer the following question: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning? We are doing this study b ...